RxDoctor Payments Data

Tamara Copeland

Family · Saint Louis, MONPI 1295192805

Payments from drug & device makers

$1,244in general payments, 2019–2025

Across 17 payments — averaging $73.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$922
  • GSK$99
  • Sanofi$81
  • Verona Pharma, Inc.$74
  • Vifor Pharma, Inc.$35
  • Tactile Systems Technology Inc$32

What the payments were for

  • Food & beverage$1,17695%
  • Education$685%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,244 in reported general payments places this provider in the 70th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$104,185
Medicare patients
672
Services billed
1,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate41$593,984
Trelegy ElliptaFluticasone/Umeclidin/Vilanter365$286,696
Spiriva RespimatTiotropium Bromide284$202,210
Breztri AerosphereBudesonide/Glycopyr/Formoterol257$189,560
FasenraBenralizumab14$85,734
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr122$70,854
Incruse ElliptaUmeclidinium Bromide148$56,856
SymbicortBudesonide/Formoterol Fumarate182$53,545
Breo ElliptaFluticasone/Vilanterol98$52,739
Spiriva HandihalerTiotropium Bromide59$41,111
Advair HfaFluticasone Propion/Salmeterol97$40,910
DuleraMometasone/Formoterol94$34,989
Albuterol Sulfate HfaAlbuterol Sulfate672$26,452
Combivent RespimatIpratropium/Albuterol Sulfate45$24,667
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate110$18,856

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta, Arnuity Ellipta$99$472,059750 claims
AstraZenecaBreztri Aerosphere, Fasenra, Symbicort, Bevespi Aerosphere$922$339,538479 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,812 family providers in Missouri.

Other family in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →